Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis
Information source: Medivir
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Herpes Labialis
Intervention: ME-609 (Drug)
Phase: Phase 3
Status: Active, not recruiting
Sponsored by: Medivir
Summary
The purpose of this study is to determine whether ME-609 is more efficient than acyclovir and
placebo for the treatment of recurrent herpes labialis.
Clinical Details
Official title: A Randomized, Double-Blind, Active Controlled, Vehicle-Controlled, Subject Initated Study Comparing Efficacy and Safety of ME-609 Versus Acyclovir Cream for Treatment of Recurrent Herpes Simplex Labialis
Study design: Randomized, Double-Blind, Active Control, Parallel Assignment
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Generally good health
- History of recurrent herpes labilalis with at last three episodes during the prior 12
months
Exclusion Criteria:
- Treatment with antivirals or immunosuppressive agents within 2 weeks prior to
randomization
- Pregnant and/or nursing women
- Continuous daily treatment with pain medication
- Significant skin condition that occur in the area of herpes recurrences
Locations and Contacts
Coastal Caroline Research Center, Mt. Pleasant, South Carolina 29464, United States
Additional Information
Starting date: July 2006
Last updated: September 10, 2007
|
